Of yeasts and hyphae: a hematologist's approach to antifungal therapy

Eric J Bow1

  • 1Health Sciences Centre, 820 Sherbrook Street, Winnipeg, Manitoba, Canada. ebow@hsc.mb.ca

Insights

Managing invasive fungal infections in cancer patients is complex due to evolving treatments. Current empirical antifungal therapy shows suboptimal outcomes, necessitating further research into optimal strategies for high-risk individuals.

Area of Science:

  • Mycology
  • Hematology
  • Oncology
  • Infectious Diseases

Background:

  • Advances in cancer therapy and immunosuppression have altered the landscape of invasive fungal infections (IFIs).
  • Hematological malignancies and hematopoietic stem cell transplantation (HSCT) patients face a spectrum of fungal pathogens.
  • The management of IFIs requires a multi-faceted approach, including prevention, preemptive, empirical, and targeted therapies.

Purpose of the Study:

  • To review current strategies for managing invasive fungal infections in patients undergoing treatment for hematological malignancies and HSCT.
  • To evaluate the effectiveness and limitations of different therapeutic approaches, including chemoprophylaxis, preemptive, empirical, and directed therapies.
  • To highlight the suboptimal outcomes in patients with IFIs despite available antifungal agents and to identify areas for future research.

Main Methods:

  • Literature review and synthesis of current evidence on invasive fungal infections in immunocompromised patients.
  • Analysis of different management strategies: prevention, preemptive, empirical, and directed therapy.
  • Critical appraisal of the efficacy and limitations of existing antifungal treatment paradigms.

Main Results:

  • Chemoprophylaxis is effective in high-risk populations when applied appropriately.
  • Preemptive strategies show promise but require validation with reliable diagnostic tools.
  • Current empirical antifungal therapy yields suboptimal outcomes, indicating a need for reassessment.
  • Despite novel antifungal agents, patients with probable or proven IFIs still experience poor outcomes.
  • Dose-intensity and combination regimens require further investigation and are not yet standard practice.

Conclusions:

  • The evolving nature of IFIs in immunocompromised patients necessitates adaptive management strategies.
  • Current empirical antifungal approaches require re-evaluation due to suboptimal patient outcomes.
  • Further research into optimized dosing, combination therapies, and validated diagnostic tools for preemptive strategies is crucial for improving IFI management.

Related Concept Videos

Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Fungal Phylum Ascomycota01:28

Fungal Phylum Ascomycota

Phylum Ascomycota, a major division within the subkingdom Dikarya, comprises a diverse range of fungal species, including both unicellular yeasts and filamentous molds such as Aspergillus and Penicillium. These fungi thrive in a variety of habitats, from aquatic ecosystems to terrestrial environments, playing crucial ecological and economic roles.Morphology and ReproductionThe defining characteristic of Ascomycetes, commonly referred to as sac fungi, is the ascus—a sac-like structure that...
Fungal Group Zygomycota01:29

Fungal Group Zygomycota

Zygomycota, previously classified as a distinct fungal group, are primarily terrestrial, saprophytic molds that play a crucial role as decomposers. Recent phylogenetic studies have revealed that these fungi are now divided into two major clades — Mucoromycota, which includes many symbiotic species, and Zoopagomycota, which primarily consists of parasitic and pathogenic fungi. These groups exhibit distinct ecological roles and reproductive strategies while sharing key structural and...
Overview of Fungi01:29

Overview of Fungi

Fungi are a diverse group of eukaryotes more closely related to animals than other eukaryotes. Fungal cell walls comprise chitin, a polysaccharide that provides structural strength, and glucans, which contribute to flexibility and integrity. Other polysaccharides, such as mannans and galactosans, may supplement or replace chitin in some fungi. These adaptations, along with their preference for acidic environments and tolerance for high osmotic pressure, enable fungi to thrive in various...
Candidiasis01:20

Candidiasis

Candidiasis is a fungal infection caused by opportunistic species of Candida. It can affect various anatomical sites, including the skin, oral cavity, nails, and genitourinary tract. Among its forms, vaginal candidiasis is the most common type of mucosal infection. It typically results from the overgrowth of Candida albicans in the vaginal mucosa. Under normal conditions, C. albicans exists as a commensal organism within the vaginal microbiota, regulated by the dominance of lactobacilli, which...